Despite the setback in the Phase III trial, Genentech continues to explore onartuzumab’s potential in two additional Phase III trials targeting different subgroups of NSCLC, including c-MET+ stage IIIB or IV NSCLC with activating EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.